MLAB
ACHAT TOTAL: 900 titres (~102 321,00 $ US) VENTE TOTALE: 7 093 titres (~800 090,40 $ US)
- Insiders
- Sullivan John James, Tripeny R Tony
- Total bought
- $102,321
- Total sold
- $800,090
- Last activity
- 2026-08-13
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
MLAB presents a weak investment case with a low catalyst score (15) driven by dominant insider selling and the absence of any meaningful event-driven trigger, compounded by fragile financials marked by high leverage…
The first sentence of the analysis written for MLAB on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 63.5% | 62.6% | 61.6% | 61.0% | 59.2% | |
| Ebit Margin | 4.8% | 7.4% | -124.9% | 2.0% | 4.0% | |
| Ebitda Margin | 14.2% | 17.6% | -110.3% | 17.1% | 17.6% | |
| Operating Profit Margin | 7.4% | 6.8% | -125.9% | 1.5% | 2.6% | |
| Pretax Profit Margin | 4.8% | 2.5% | -127.5% | -0.2% | 1.9% | |
| Continuous Operations Profit Margin | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | |
| Net Profit Margin | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | |
| Bottom Line Profit Margin | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | |
| Current Ratio | 1.717 | 0.626 | 2.468 | 2.744 | 2.587 | |
| Quick Ratio | 1.291 | 0.472 | 1.730 | 1.945 | 2.075 | |
| Solvency Ratio | 0.124 | 0.082 | -0.739 | 0.127 | 0.086 | |
| Cash Ratio | 0.435 | 0.167 | 0.637 | 0.759 | 1.027 | |
| Price To Earnings Ratio | 72.475 | -329.611 | -2.373 | 1,027.824 | 708.000 | |
| Price To Earnings Growth Ratio | -0.165 | 3.321 | 0.000 | -19.475 | -15.576 | |
| Forward Price To Earnings Growth Ratio | -0.165 | 3.321 | 0.000 | -19.475 | -15.576 | |
| Price To Earnings Diluted Ratio | 73.074 | -329.611 | -2.373 | 1,027.824 | 728.229 | |
| Price To Earnings Diluted Growth Ratio | -0.168 | 3.321 | 0.000 | -19.985 | -16.071 | |
| Price To Book Ratio | 2.618 | 4.031 | 4.149 | 2.363 | 3.373 | |
| Price To Sales Ratio | 1.957 | 2.673 | 2.790 | 4.244 | 7.207 | |
| Price To Free Cash Flow Ratio | 12.318 | 15.226 | 14.513 | 39.666 | 38.183 | |
| Price To Operating Cash Flow Ratio | 11.383 | 13.763 | 13.669 | 33.225 | 33.869 | |
| Debt To Assets Ratio | 0.395 | 0.419 | 0.518 | 0.281 | 0.313 | |
| Debt To Equity Ratio | 0.906 | 1.135 | 1.591 | 0.473 | 0.562 | |
| Debt To Capital Ratio | 0.475 | 0.532 | 0.614 | 0.321 | 0.360 | |
| Long Term Debt To Capital Ratio | 0.439 | 0.325 | 0.604 | 0.318 | 0.357 | |
| Financial Leverage Ratio | 2.297 | 2.711 | 3.073 | 1.682 | 1.796 | |
| Working Capital Turnover Ratio | -29.469 | 128.112 | 3.074 | 2.885 | 1.061 | |
| Operating Cash Flow Ratio | 0.692 | 0.285 | 0.996 | 0.645 | 0.816 | |
| Operating Cash Flow Sales Ratio | 0.172 | 0.194 | 0.204 | 0.128 | 0.213 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.924 | 0.904 | 0.942 | 0.838 | 0.887 | |
| Debt Service Coverage Ratio | 1.838 | 0.305 | -38.086 | 8.141 | 7.934 | |
| Interest Coverage Ratio | 1.731 | 1.378 | -47.758 | 0.696 | 1.210 | |
| Short Term Operating Cash Flow Coverage Ratio | 7.614 | 0.463 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.254 | 0.258 | 0.191 | 0.150 | 0.177 | |
| Capital Expenditure Coverage Ratio | 13.179 | 10.404 | 17.192 | 6.158 | 8.850 | |
| Dividend Paid And Capex Coverage Ratio | 6.324 | 5.875 | 7.338 | 3.520 | 5.047 | |
| Dividend Payout Ratio | 0.525 | -1.757 | -0.014 | 3.662 | 1.785 | |
| Enterprise Value Multiple | 17.839 | 18.853 | -3.383 | 28.868 | 46.122 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 63.5% | ▲0.9% | ▲1.9% |
| Ebit Margin | 4.8% | ▼-2.6% | ▲26.1% |
| Ebitda Margin | 14.2% | ▼-3.4% | ▲22.9% |
| Operating Profit Margin | 7.4% | ▲0.7% | ▲28.9% |
| Pretax Profit Margin | 4.8% | ▲2.4% | ▲28.5% |
| Continuous Operations Profit Margin | 2.7% | ▲3.5% | ▲25.6% |
| Net Profit Margin | 2.7% | ▲3.5% | ▲25.6% |
| Bottom Line Profit Margin | 2.7% | ▲3.5% | ▲25.6% |
| Current Ratio | 1.717 | ▲1.091 | ▼-0.311 |
| Quick Ratio | 1.291 | ▲0.819 | ▼-0.212 |
| Solvency Ratio | 0.124 | ▲0.042 | ▲0.188 |
| Cash Ratio | 0.435 | ▲0.268 | ▼-0.170 |
| Price To Earnings Ratio | 72.475 | ▲402.087 | ▼-222.788 |
| Price To Earnings Growth Ratio | -0.165 | ▼-3.487 | ▲6.214 |
| Forward Price To Earnings Growth Ratio | -0.165 | ▼-3.487 | ▲6.214 |
| Price To Earnings Diluted Ratio | 73.074 | ▲402.685 | ▼-226.354 |
| Price To Earnings Diluted Growth Ratio | -0.168 | ▼-3.489 | ▲6.413 |
| Price To Book Ratio | 2.618 | ▼-1.413 | ▼-0.689 |
| Price To Sales Ratio | 1.957 | ▼-0.716 | ▼-1.817 |
| Price To Free Cash Flow Ratio | 12.318 | ▼-2.909 | ▼-11.664 |
| Price To Operating Cash Flow Ratio | 11.383 | ▼-2.380 | ▼-9.799 |
| Debt To Assets Ratio | 0.395 | ▼-0.024 | ▲0.010 |
| Debt To Equity Ratio | 0.906 | ▼-0.229 | ▼-0.027 |
| Debt To Capital Ratio | 0.475 | ▼-0.056 | ▲0.015 |
| Long Term Debt To Capital Ratio | 0.439 | ▲0.114 | ▲0.031 |
| Financial Leverage Ratio | 2.297 | ▼-0.415 | ▼-0.015 |
| Working Capital Turnover Ratio | -29.469 | ▼-157.581 | ▼-50.602 |
| Operating Cash Flow Ratio | 0.692 | ▲0.406 | ▲0.005 |
| Operating Cash Flow Sales Ratio | 0.172 | ▼-0.022 | ▼-0.010 |
| Free Cash Flow Operating Cash Flow Ratio | 0.924 | ▲0.020 | ▲0.025 |
| Debt Service Coverage Ratio | 1.837 | ▲1.533 | ▲5.811 |
| Interest Coverage Ratio | 1.731 | ▲0.354 | ▲10.280 |
| Short Term Operating Cash Flow Coverage Ratio | 7.614 | ▲7.151 | ▲5.999 |
| Operating Cash Flow Coverage Ratio | 0.254 | ▼-0.004 | ▲0.048 |
| Capital Expenditure Coverage Ratio | 13.179 | ▲2.775 | ▲2.022 |
| Dividend Paid And Capex Coverage Ratio | 6.324 | ▲0.449 | ▲0.703 |
| Dividend Payout Ratio | 0.525 | ▲2.282 | ▼-0.315 |
| Enterprise Value Multiple | 17.839 | ▼-1.014 | ▼-3.821 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $487.5M | $644.2M | $603.2M | $929.7M | $1.33B | |
| Enterprise value | $629.5M | $798.4M | $806.3M | $1.08B | $1.50B | |
| EV / Sales | 2.53x | 3.31x | 3.73x | 4.94x | 8.14x | |
| EV / Op. cash flow | 14.70x | 17.06x | 18.27x | 38.70x | 38.25x | |
| EV / Free cash flow | 15.90x | 18.87x | 19.40x | 46.20x | 43.12x | |
| EV / EBITDA | 17.84x | 18.85x | -3.38x | 28.87x | 46.12x | |
| Net debt / EBITDA | 4.02x | 3.64x | -0.85x | 4.08x | 5.28x | |
| Current ratio | 1.72x | 0.63x | 2.47x | 2.74x | 2.59x | |
| Income quality | 6.38x | -23.71x | -0.17x | 30.09x | 20.96x | |
| Graham number | $30 | — | — | $17 | $25 | |
| Graham net-net | -$31 | -$37 | -$42 | -$35 | -$42 | |
| Tax burden | 55.9% | -33.1% | 92.2% | -239.1% | 52.4% | |
| Interest burden | 100.0% | 33.5% | 102.1% | -8.9% | 47.9% | |
| Working capital | $44.4M | -$61.3M | $65.0M | $75.6M | $76.3M | |
| Invested capital | $362.7M | $249.7M | $400.3M | $607.0M | $646.2M | |
| Return on assets | 1.6% | -0.5% | -56.9% | 0.1% | 0.3% | |
| Operating ROA | 4.3% | 3.7% | -49.1% | 0.5% | 0.7% | |
| Return on tangible assets | 4.3% | -1.3% | -166.2% | 0.6% | 1.1% | |
| Return on equity | 3.6% | -1.2% | -174.9% | 0.2% | 0.5% | |
| Return on invested capital | 2.8% | -1.4% | -61.9% | -1.3% | 0.4% | |
| Return on capital employed | 5.1% | 6.1% | -67.6% | 0.5% | 0.7% | |
| Earnings yield | 1.4% | -0.3% | -42.1% | 0.1% | 0.1% | |
| Free cash flow yield | 8.1% | 6.6% | 6.9% | 2.5% | 2.6% | |
| Capex / Op. cash flow | 7.6% | 9.6% | 5.8% | 16.2% | 11.3% | |
| Capex / Depreciation | 14.0% | 18.3% | 8.1% | 13.7% | 17.7% | |
| Capex / Sales | 1.3% | 1.9% | 1.2% | 2.1% | 2.4% | |
| SG&A / Sales | 47.9% | 47.7% | 51.6% | 50.2% | 48.1% | |
| R&D / Sales | 8.2% | 8.1% | 8.9% | 9.4% | 8.6% | |
| Stock comp / Sales | 7.2% | 5.5% | 5.5% | 5.7% | 6.2% | |
| Intangibles / Total assets | 63.2% | 64.3% | 65.8% | 76.0% | 76.5% | |
| Days sales outstanding | 65d | 64d | 66d | 71d | 82d | |
| Days payables outstanding | 20d | 23d | 27d | 26d | 38d | |
| Operating cycle | 171d | 166d | 210d | 219d | 201d | |
| Cash conversion cycle | 151d | 143d | 183d | 193d | 163d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-24.3%EV / Sales ▼-23.7%EV / EBITDA ▼-5.4%EV / Op. cash flow ▼-2.360Earnings yield ▲+0.017
Profitability
Return on equity ▲+0.048Return on assets ▲+0.020Return on invested capital ▲+0.042Return on capital employed ▼-0.010Operating ROA ▲+0.006Income quality ▲+30.094Tax burden ▲+0.890
Efficiency
Days sales outstanding ▲+1.039Days payables outstanding ▼-3.483Operating cycle ▲+4.238Cash conversion cycle ▲+7.721Capex / Sales ▼-0.006R&D / Sales ▲+0.001
Balance-sheet strength
Current ratio ▲+1.091Net debt / EBITDA ▲+0.381Working capital ▲+105648000.000Invested capital ▲+113003000.000Intangibles / Total assets ▼-0.011
Change over 5 years
Valuation
Market cap ▼-63.3%EV / Sales ▼-69.0%EV / EBITDA ▼-61.3%EV / Op. cash flow ▼-23.552Earnings yield ▲+0.012Graham number ▲+5.712
Profitability
Return on equity ▲+0.031Return on assets ▲+0.013Return on invested capital ▲+0.024Return on capital employed ▲+0.043Operating ROA ▲+0.036Income quality ▼-14.582Tax burden ▲+0.035
Efficiency
Days sales outstanding ▼-17.018Days payables outstanding ▼-18.510Operating cycle ▼-30.432Cash conversion cycle ▼-11.922Capex / Sales ▼-0.011R&D / Sales ▼-0.004
Balance-sheet strength
Current ratio ▼-0.870Net debt / EBITDA ▼-1.260Working capital ▼-31893000.000Invested capital ▼-283473000.000Intangibles / Total assets ▼-0.134
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-10 Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
- 2026-08-10 Mesa Laboratories Q1 Earnings Call Highlights Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
- 2026-08-03 Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced it will release financial results for its first fiscal quarter (“1Q27”) ended June 30, 2026 following market close on Monday, August 10, 2026. The Company will also hold its first earnings conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
- 2026-07-06 MESA LABS DECLARES QUARTERLY DIVIDEND Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.
- 2026-05-27 Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today Mesa Laboratories fell after reporting its Q4 fiscal 2026 results. Sales and earnings came in below Wall Street''s expected earnings, but the business did report strong growth for adjusted operating income.
- 2026-05-27 Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q26”) and fiscal year (“FY26”) ended March 31, 2026 (amounts in thousands).